JP2025501922A5 - - Google Patents
Info
- Publication number
- JP2025501922A5 JP2025501922A5 JP2024538962A JP2024538962A JP2025501922A5 JP 2025501922 A5 JP2025501922 A5 JP 2025501922A5 JP 2024538962 A JP2024538962 A JP 2024538962A JP 2024538962 A JP2024538962 A JP 2024538962A JP 2025501922 A5 JP2025501922 A5 JP 2025501922A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263298551P | 2022-01-11 | 2022-01-11 | |
| US63/298,551 | 2022-01-11 | ||
| PCT/US2023/010493 WO2023137018A1 (en) | 2022-01-11 | 2023-01-10 | Uses of a somatostatin modulator for the treatment of carcinoid syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501922A JP2025501922A (ja) | 2025-01-24 |
| JP2025501922A5 true JP2025501922A5 (https=) | 2026-01-07 |
Family
ID=87279605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538962A Pending JP2025501922A (ja) | 2022-01-11 | 2023-01-10 | カルチノイド症候群の治療のためのソマトスタチンモジュレータの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250228842A1 (https=) |
| EP (1) | EP4463159A4 (https=) |
| JP (1) | JP2025501922A (https=) |
| KR (1) | KR20240132451A (https=) |
| CN (1) | CN118510511A (https=) |
| AU (1) | AU2023207068A1 (https=) |
| CA (1) | CA3242165A1 (https=) |
| IL (1) | IL314054A (https=) |
| MX (1) | MX2024008598A (https=) |
| TW (1) | TW202339747A (https=) |
| WO (1) | WO2023137018A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250152674A1 (en) * | 2022-02-25 | 2025-05-15 | Amryt Endo, Inc. | Oral octreotide for treatment of disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
| IL264178B2 (en) * | 2016-07-14 | 2024-05-01 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| PT3740475T (pt) * | 2018-01-17 | 2022-07-18 | Crinetics Pharmaceuticals Inc | Processo de produção de moduladores da somatostatina |
| JP2022540922A (ja) * | 2019-07-17 | 2022-09-20 | クリネティックス ファーマシューティカルズ，インク． | ソマトスタチンモジュレーターの結晶形態 |
| CA3191084A1 (en) * | 2020-09-09 | 2022-03-17 | Gerald Burke | Formulations of a somatostatin modulator |
-
2023
- 2023-01-10 WO PCT/US2023/010493 patent/WO2023137018A1/en not_active Ceased
- 2023-01-10 CN CN202380016138.8A patent/CN118510511A/zh active Pending
- 2023-01-10 US US18/727,827 patent/US20250228842A1/en active Pending
- 2023-01-10 AU AU2023207068A patent/AU2023207068A1/en active Pending
- 2023-01-10 TW TW112101029A patent/TW202339747A/zh unknown
- 2023-01-10 JP JP2024538962A patent/JP2025501922A/ja active Pending
- 2023-01-10 KR KR1020247021853A patent/KR20240132451A/ko active Pending
- 2023-01-10 IL IL314054A patent/IL314054A/en unknown
- 2023-01-10 CA CA3242165A patent/CA3242165A1/en active Pending
- 2023-01-10 MX MX2024008598A patent/MX2024008598A/es unknown
- 2023-01-10 EP EP23740602.0A patent/EP4463159A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW576743B (en) | Extended release formulations of erythromycin derivatives | |
| EP1286668B1 (en) | Pharmaceutical combinations comprising tegaserod und omeprazole and their use in treating gastrointestinal disorders | |
| EP1077704A1 (en) | Combination therapy for treatment of depression | |
| JP2012006923A (ja) | 糖尿病の治療及び予防のためのフタリド誘導体の使用 | |
| TW201202238A (en) | 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal | |
| US20250241897A1 (en) | Composition for eradicating helicobacter pylori | |
| JP2025541969A (ja) | アラジール症候群（ａｌｇｓ）の処置 | |
| JP2025501922A5 (https=) | ||
| EP4240354A1 (en) | Raf inhibitor for treating low grade glioma | |
| HUE034155T2 (en) | Therapeutic uses of 1- [2- (2,4-dimethylphenylsulfanyl) phenyl] piperazine | |
| TWI777059B (zh) | 肌肉減少症之預防劑及治療劑 | |
| CN118845777B (zh) | 一种克诺拉尼用作淋巴水肿治疗剂的用途 | |
| US4559326A (en) | Antiinflammatory compositions and methods | |
| JP2011517678A (ja) | 過活動膀胱の治療のためのウデナフィル、およびアルフゾシンまたはオキシブチニンの組み合わせの使用 | |
| JP2025039725A (ja) | １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む経口用製剤、およびその製造方法 | |
| US20240100011A1 (en) | Pediatric formulations of ferric citrate | |
| CN105579036B (zh) | 用于改善膀胱尿道协同失调的药剂 | |
| JP5094197B2 (ja) | 杯細胞過形成を抑制するための抗ヒスタミン剤含有医薬組成物 | |
| US5876751A (en) | Antispasmodic and antinflammatory composition and a process for the manufacture thereof | |
| KR20220168172A (ko) | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 약학적 조성물 | |
| CN112999226A (zh) | 用于治疗类风湿性关节炎的药物组合物 | |
| CN101370520A (zh) | 用于心力衰竭的预防或治疗的医药组合物 | |
| CN112716945B (zh) | 药物组合物及其应用 | |
| WO2005063253A1 (ja) | アレルギー症状治療用医薬組成物 | |
| EP3981423B1 (en) | Composition for preventing or treating uric acid-related disease |